Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity to PXVX0317 in adults ≥65 years of age.
Epistemonikos ID: 925e2a3cdad5ea02c32d6afb17c6c04f14e56292
First added on: May 13, 2024